Pfizer documents: Cumulative Analysis of Post-authorization Adverse Event Reports

Released April 1, 2022

Although the report contains a list of adverse events spanning 9 pages (Appendix 1), Pfizer still concludes that these findings of their “signal detection analyses are consistent with the known safety profile” of their product BNT162b2 and the “cumulative post-marketing experience confirms a favourable benefit-risk balance”.

Latest articles

  • 2
  • 3
  • 4
  • 5
  • 6